Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEBBLE
2024-518115-19-02Phase 4Authorised
- Sponsor
- Semmelweis University
- Start
- Jul 2025
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of meropenem, piperacillin + tazobactam, cefepime and ceftriaxone in bacterial disease and sepsis (2 arms), sponsored by Semmelweis University. Primary endpoint: Therapeutic and optimal exposure (100% fT>MIC). Planned start Jul 2025; status: authorised.
02
Drugs
meropenempiperacillin + tazobactamcefepimeceftriaxone
03
Conditions
bacterial diseasesepsis
Beyond the preview
Go deeper on 2024-518115-19-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518115-19-02.